GSK’s RSV Vaccine Outselling Pfizer’s

Reuters (10/30, Erman) reports, “Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.” Currently, “GSK...